ANI expects high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and substantial accretion thereafter. The transaction is anticipated to deliver additional $35M-$38M in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10M in identified cost synergies with additional EBITDA contribution expected from accelerated growth of Cortrophin Gel within ophthalmology. The company anticipates 3.2x pro-forma leverage upon closing and significant organic de-levering in 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
- ANI Pharmaceuticals management to meet with Truist
- ANI Pharmaceuticals: Essential Financial Update for Market Players
- ANI Pharmaceuticals Announces the Launch of Kionex® Suspension
- ANI Pharmaceuticals launches Kionex suspension